-
Diagnostics World News | Soley Therapeutics will advance its proprietary cell stress sensing platform; Precede Biosciences’s platform aims to meet rapidly growing demand from developers of next-generation precision medicines; Proxima will accelerate the advancement of first-in-class proximity-modulating therapeutics; and more.
Jan 28, 2026
-
Diagnostics World News | NeuroQure has launched ASD Insight, a first-of-its-kind test designed to identify autism risk as early as birth; Cytespace expanded its molecular testing to meet increasing demands across Sub-Saharan Africa; Daisy Genomics and New Day Diagnostics have entered a collaboration with the University of Tennessee and the East Tennessee Health Innovation Alliance; and more.
Jan 27, 2026
-
Diagnostics World News | A lot is at stake in obesity drug development, heightening the focus of pharma sponsors on producing the right evidence to support a label claim and differentiating their products in the rapidly growing weight management pharmacotherapy market. It’s also the rationale for the industrywide DECODE Obesity initiative of Ametris (formerly ActiGraph) looking to expand the range of outcome measures beyond weight loss.
Jan 23, 2026
-
Diagnostics World News | Illumina has announced CMS reimbursement for TruSight Oncology Comprehensive. The FDA-approved comprehensive genomic profiling test will be reimbursed at a rate of $2,989.55 per test. The news comes just a week after presenting a clinical-focused vision and strong Q4 results at the J.P. Morgan Healthcare Conference.
Jan 21, 2026
-
Diagnostics World News | There can be little debate that Alzheimer’s disease is one of the greatest healthcare challenges we face globally. Most recent estimates suggest that over 57 million people worldwide are living with dementia, of which 70% is caused by Alzheimer’s. With aging societies, this number is expected to increase to over 150 million by 2050. Yet there is a growing sense of impending change, particularly because the way we diagnose Alzheimer’s is now at a pivotal moment.
Jan 20, 2026
-
Diagnostics World News | Diagnostics took center stage at the 44th Annual J.P. Morgan Healthcare Conference this week, and even companies not formally presenting at the event timed announcements to highlighting new products and readouts from recent studies.
Jan 16, 2026
-
Diagnostics World News | Researchers in the University of Surry (UK) have identified a set of blood-based protein signals that may foreshadow an individual’s risk of death five to 10 years before it occurs. This discovery carries promise for next-generation diagnostics aimed at early risk detection rather than disease diagnosis.
Jan 14, 2026
-
Diagnostics World News | Grail returned to the 44th Annual J.P. Morgan Healthcare Conference for its second appearance as an independent public company, and CEO Bob Ragusa had positive momentum to report, though the tipping point is still expecting mid-2026 with the readouts of two major clinical trials. The multi-cancer early detection company is closing in on a critical regulatory milestone while demonstrating strong commercial traction.
Jan 12, 2026
-
Diagnostics World News | There can be little debate that Alzheimer’s disease is one of the greatest healthcare challenges we face globally. Most recent estimates suggest that over 57 million people worldwide are living with dementia, of which 70% is caused by Alzheimer’s. With aging societies, this number is expected to increase to over 150 million by 2050. Yet there is a growing sense of impending change, particularly because the way we diagnose Alzheimer’s is now at a pivotal moment.
Jan 9, 2026
-
Diagnostics World News | In just a few years, the monitoring of brain signals via ubiquitous earbuds will be as common as heart rhythm tracking by popular smartwatch brands like Apple and Fitbit. People wearing these next-generation earbuds will have their electroencephalogram (EEG) effortlessly analyzed while they listen to music or make phone calls.
Jan 8, 2026
-
Diagnostics World News | After less than three years of collecting voice samples from individuals with amyotrophic lateral sclerosis, and a control group of healthy volunteers, the Peter Cohen Foundation awaits approval from the Food and Drug Administration of its algorithm as a secondary biomarker for tracking the progression of the devastating neurological disease. The drug development tool, a “listener effort” prediction model, will be used in a multitude of clinical trials as soon as the first quarter of 2026.
Jan 7, 2026
-
Diagnostics World News | To kick off 2026, we spoke with industry experts and leaders in the Diagnostics World community about what they expect and look forward to in the new year. Here are the full trends and predictions, including more on AI, data management and collection, precision diagnostics, new testing, and more.
Jan 6, 2026
-
Diagnostics World News | Diagnostics is gaining growing traction within several companies not historically diagnostics-focused, and it is the subject of a fair amount of AI investment as well. NVIDIA’s partnerships with diagnostics companies came up in more than one top story of the year, and AI’s role for image processing came up in others. Even earlier multi-cancer early detection tests were notable and the growing trend in women’s health was reflected in attention to endometriosis diagnosis.
Dec 29, 2025
-
Diagnostics World News | Circular Genomics will accelerate the clinical development and commercialization of their circRNA biomarker platform for the early detection of Alzheimer's disease; Wearlinq introduces eWave, the first continuous, multi-lead (6-lead) ECG in a small, wireless form factor; Subsense is building a bidirectional BCI platform designed to record and modulate brain activity without surgical implants; and more.
Dec 23, 2025
-
Diagnostics World News | The Singapore-MIT Alliance for Research and Technology launches a new collaborative research project; Cleveland Diagnostics receives FDA approval of their IsoPSA in vitro diagnostic kit; Roche announces that its first point-of-care test for the detection of Bordetella infections has been granted FDA 510(k) clearance and Clinical Laboratory Improvement Amendments of 1988 waiver; and more.
Dec 22, 2025
-
Diagnostics World News | Researchers have identified a previously overlooked mechanism controlling allergic reactions in the gut, potentially paving the way for novel treatments for conditions ranging from food allergies to irritable bowel syndrome.
Dec 18, 2025
-
Diagnostics World News | Good sleep patterns impact many aspects of the broader health status of individuals, but the measurement of slumber quality tends to fall at the extremes of either simplistic sleep logs or cumbersome in-patient sleep studies, or polysomnography. A new sleep-staging framework driven by artificial intelligence and an associated Apple Watch app known as BIDSleep is designed to bridge that gap by turning a smartwatch into a sleep-staging device that can distinguish between light, deep, and rapid eye movement sleep.
Dec 16, 2025
-
Diagnostics World News | Illumina today announced an investment and collaboration into MyOme, a genomics and risk modeling company. The collaboration and investment will help advance MyOme’s Proactive Health (MPH) Trial—a clinical trial seeking to quantify the cost savings and improved patient outcomes for whole-genome sequencing (WGS) combined with MyOme’s AI-integrated risk models (IRMs)—and help expand MyOme’s suite of proactive health and rare disease diagnostic tests. Neither financial details nor milestones of the investment were disclosed.
Dec 11, 2025
-
Diagnostics World News | Thanks to promising developments in psychedelic and dissociative compounds, treatments for depression are likely to significantly change in the next 10 years. However, psychedelics also come with their own set of complications and side effects, such as disconnection from oneself and one’s surroundings and cardiovascular changes.
Dec 10, 2025
-
Diagnostics World News | Oxford Nanopore Technologies named a new CEO this morning, choosing an executive with extensive diagnostics experience. Francis Van Parys, currently CEO of Radiometer, will join Oxford Nanopore and the Board as an Executive Director on March 2, 2026.
Dec 8, 2025